BioCentury | May 9, 2018
Distillery Therapeutics

Renal; cardiovascular; hepatic

...skin cancer and polycystic kidney disease (PKD) and Phase II testing for kaposiform hemangioendothelioma (KHE). Tacrolimus...
BioCentury | Apr 27, 2018
Clinical News

Regenerative Patch Technologies' CPCB-RPE1 successfully implanted in AMD patients

...membrane. Patients in the open-label, U.S. trial received the CPCB-RPE1 subretinal implant in combination with tacrolimus...
BioCentury | Jan 19, 2018
Clinical News

Kadmon reports Phase IIa data for chronic GvDH candidate

...patients completely discontinued steroids. Furthermore, 83% of patients were able to reduce their dose of tacrolimus...
BioCentury | Jan 4, 2018
Distillery Techniques

Disease models

...in patients with HSCT-associated GvHD. In the model, the combination of the generic calcineurin inhibitor tacrolimus...
...of donor-specific recipient T cells in the blood compared with the standard immunosuppressive protocol of tacrolimus...
...renal transplant rejection and in Phase II testing to treat liver transplant rejection. The generic tacrolimus...
BioCentury | Mar 29, 2017
Distillery Therapeutics

Inflammation

...INDICATION: Inflammation Mouse studies suggest topical tacrolimus could help treat lymphedema. In a mouse tail model...
...could help treat lymphedema. In a mouse tail model of lymphedema, a topical formulation of tacrolimus...
...function compared with topical vehicle. In another mouse model of lymphedema, the topical formulation of tacrolimus...
BioCentury | Jan 13, 2017
Company News

Selten, Vivus deal

...Selten granted Vivus exclusive, worldwide rights to develop and commercialize tacrolimus and ascomycin to treat pulmonary...
...Selten will receive an undisclosed upfront payment and is eligible for milestones and tiered royalties. Tacrolimus...
BioCentury | May 9, 2016
Clinical News

Pancreatic islet cells: Phase III data

...the portal vein plus a regimen of immunosuppressive medications consisting of antithymocyte globulin, sirolimus, low-dose tacrolimus...
BioCentury | Nov 16, 2015
Company News

Astellas, Leo Pharma deal

...million ($726.6 million). Astellas’ dermatology portfolio includes Protopic , a topical formulation of the immunosuppressant tacrolimus...
BioCentury | Nov 12, 2015
Company News

Leo buys Astellas' dermatology business

...675 million ($726.6 million). Astellas' dermatology portfolio includes Protopic , a topical formulation of immunosuppressant tacrolimus...
BioCentury | Sep 28, 2015
Clinical News

AMT-110: Phase I/II data

...single administration of intracerebral AMT-110 plus continuous immune suppression therapy with mycophenolate mofetil (MMF) and tacrolimus...
Items per page:
1 - 10 of 217